CN107073006A - 组蛋白脱甲基酶抑制剂 - Google Patents
组蛋白脱甲基酶抑制剂 Download PDFInfo
- Publication number
- CN107073006A CN107073006A CN201580060763.8A CN201580060763A CN107073006A CN 107073006 A CN107073006 A CN 107073006A CN 201580060763 A CN201580060763 A CN 201580060763A CN 107073006 A CN107073006 A CN 107073006A
- Authority
- CN
- China
- Prior art keywords
- compound
- pharmaceutically acceptable
- alkyl
- acceptable salt
- aryl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 0 *c1c(-c2cc(-c3c(*)[n](*)c(*)n3)ncc2)nn[n]1 Chemical compound *c1c(-c2cc(-c3c(*)[n](*)c(*)n3)ncc2)nn[n]1 0.000 description 3
- ZSBPPHUCNDMKKN-UHFFFAOYSA-N C#Cc1cc(-c2c[n](Cc3cccc(Cl)c3Cl)cn2)ncc1 Chemical compound C#Cc1cc(-c2c[n](Cc3cccc(Cl)c3Cl)cn2)ncc1 ZSBPPHUCNDMKKN-UHFFFAOYSA-N 0.000 description 1
- JKQLIDDJQPWZHO-UHFFFAOYSA-N C(C1CC1)[n]1cnc(-c(nc2)cc3c2nn[nH]3)c1 Chemical compound C(C1CC1)[n]1cnc(-c(nc2)cc3c2nn[nH]3)c1 JKQLIDDJQPWZHO-UHFFFAOYSA-N 0.000 description 1
- NBFQZZXPJYKQDP-UHFFFAOYSA-N Clc1ccc(C[n]2cnc(-c3ncc4nn[nH]c4c3)c2)cc1 Chemical compound Clc1ccc(C[n]2cnc(-c3ncc4nn[nH]c4c3)c2)cc1 NBFQZZXPJYKQDP-UHFFFAOYSA-N 0.000 description 1
- RHTLYFRNSKDWRU-UHFFFAOYSA-N N#CC1=C(c2cc(C3N=CN(Cc4ccccc4Cl)C3)ncc2)N=NCC1 Chemical compound N#CC1=C(c2cc(C3N=CN(Cc4ccccc4Cl)C3)ncc2)N=NCC1 RHTLYFRNSKDWRU-UHFFFAOYSA-N 0.000 description 1
- NZNLRAUJKJESTM-TVPGTPATSA-N N#Cc1cc(C(N=C2)=C/C2=C/CCc(cccc2)c2Cl)ncc1 Chemical compound N#Cc1cc(C(N=C2)=C/C2=C/CCc(cccc2)c2Cl)ncc1 NZNLRAUJKJESTM-TVPGTPATSA-N 0.000 description 1
- GPGBPBPIEKUSPD-UHFFFAOYSA-N OCc1cc(-c2c[n](Cc3ccccc3Cl)cn2)ncc1 Chemical compound OCc1cc(-c2c[n](Cc3ccccc3Cl)cn2)ncc1 GPGBPBPIEKUSPD-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4192—1,2,3-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462051268P | 2014-09-16 | 2014-09-16 | |
| US62/051,268 | 2014-09-16 | ||
| PCT/US2015/050289 WO2016044342A1 (en) | 2014-09-16 | 2015-09-15 | Histone demethylase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN107073006A true CN107073006A (zh) | 2017-08-18 |
Family
ID=55533770
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201580060763.8A Pending CN107073006A (zh) | 2014-09-16 | 2015-09-15 | 组蛋白脱甲基酶抑制剂 |
Country Status (17)
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111116571A (zh) * | 2019-12-27 | 2020-05-08 | 吉首大学 | 含恶唑及三唑双杂环的化合物及其制备与应用方法 |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2903081A1 (en) | 2013-03-14 | 2014-09-25 | Quanticel Pharmaceuticals, Inc. | Histone demethylase inhibitors |
| WO2016044342A1 (en) * | 2014-09-16 | 2016-03-24 | Quanticel Pharmaceuticals, Inc. | Histone demethylase inhibitors |
| US9896436B2 (en) | 2014-09-16 | 2018-02-20 | Celgene Quanticel Research, Inc. | Histone demethylase inhibitors |
| US9586949B2 (en) | 2015-02-09 | 2017-03-07 | Incyte Corporation | Aza-heteroaryl compounds as PI3K-gamma inhibitors |
| PT3371190T (pt) | 2015-11-06 | 2022-07-08 | Incyte Corp | Compostos heterocíclicos como inibidores de pi3k-gamma |
| ES2833955T3 (es) * | 2016-01-05 | 2021-06-16 | Incyte Corp | Piridinas sustituidas con pirazol/imidazol como inhibidores de PI3K-Gamma |
| WO2017161033A1 (en) * | 2016-03-15 | 2017-09-21 | Celgene Quanticel Research, Inc. | Histone demethylase inhibitors |
| US10150754B2 (en) | 2016-04-19 | 2018-12-11 | Celgene Quanticel Research, Inc. | Histone demethylase inhibitors |
| WO2017223414A1 (en) | 2016-06-24 | 2017-12-28 | Incyte Corporation | HETEROCYCLIC COMPOUNDS AS PI3K-γ INHIBITORS |
| MD3697789T2 (ro) | 2017-10-18 | 2022-02-28 | Incyte Corp | Derivați imidazol condensați substituiți cu grupări hidroxi terțiare ca inhibitori PI3K-GAMA |
| CR20250050A (es) | 2018-09-05 | 2025-03-19 | Incyte Corp | Formas cristalinas de un inhibidor de fosfoinositida 3–quinasa (pi3k) (divisional 2021-0165) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060074244A1 (en) * | 2002-07-31 | 2006-04-06 | Gellibert Francoise J | Pyridinyl substituted (1,2,3,)triazoles as inhibitors of the tgf-beta signalling pathway |
| US20140194469A1 (en) * | 2012-12-06 | 2014-07-10 | Quanticel Pharmaceuticals, Inc. | Histone demethylase inhibitors |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1140862A4 (en) | 1998-12-23 | 2004-07-28 | Bristol Myers Squibb Pharma Co | THROMBIN OR Xa FACTOR INHIBITORS |
| WO2002041843A2 (en) | 2000-10-26 | 2002-05-30 | Tularik Inc. | Antiinflammation agents |
| US20040127733A1 (en) | 2002-10-31 | 2004-07-01 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | New beta-agonists, processes for preparing them and their use as pharmaceutical compositions |
| DE102004021779A1 (de) | 2004-04-30 | 2005-11-24 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Beta-Agonisten, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel |
| JP2009519998A (ja) | 2005-12-19 | 2009-05-21 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | アミノアルコール誘導体の過活動膀胱の治療の為の使用 |
| AU2008308900A1 (en) | 2007-10-03 | 2009-04-09 | Vertex Pharmaceuticals Incorporated | c-MET protein kinase inhibitors |
| DE102009019962A1 (de) | 2009-05-05 | 2010-11-11 | Merck Patent Gmbh | 3-([1,2,3]Triazol-4-yl)-pyrrolo[2,3-b]pyridinderivate |
| PT2499139E (pt) | 2009-11-10 | 2014-02-10 | Pfizer | Inibidores de n1-pirazolospirocetona acetil-coa carboxilase |
| ES2560627T3 (es) | 2010-01-13 | 2016-02-22 | Tempero Pharmaceuticals, Inc. | Compuestos y procedimientos para la inhibición de HDAC |
| CA2903081A1 (en) | 2013-03-14 | 2014-09-25 | Quanticel Pharmaceuticals, Inc. | Histone demethylase inhibitors |
| WO2016007722A1 (en) | 2014-07-10 | 2016-01-14 | Incyte Corporation | Triazolopyridines and triazolopyrazines as lsd1 inhibitors |
| WO2016044342A1 (en) | 2014-09-16 | 2016-03-24 | Quanticel Pharmaceuticals, Inc. | Histone demethylase inhibitors |
| US9896436B2 (en) * | 2014-09-16 | 2018-02-20 | Celgene Quanticel Research, Inc. | Histone demethylase inhibitors |
-
2015
- 2015-09-15 WO PCT/US2015/050289 patent/WO2016044342A1/en not_active Ceased
- 2015-09-15 JP JP2017514411A patent/JP6660060B2/ja not_active Expired - Fee Related
- 2015-09-15 KR KR1020177009901A patent/KR20170048590A/ko not_active Withdrawn
- 2015-09-15 MX MX2017003464A patent/MX2017003464A/es unknown
- 2015-09-15 BR BR112017005128A patent/BR112017005128A2/pt not_active Application Discontinuation
- 2015-09-15 EP EP15842092.7A patent/EP3193881B1/en not_active Not-in-force
- 2015-09-15 ES ES15842092T patent/ES2911292T3/es active Active
- 2015-09-15 SG SG11201702108PA patent/SG11201702108PA/en unknown
- 2015-09-15 US US14/855,269 patent/US9676770B2/en active Active
- 2015-09-15 EA EA201790502A patent/EA201790502A1/ru unknown
- 2015-09-15 AU AU2015317904A patent/AU2015317904A1/en not_active Abandoned
- 2015-09-15 CN CN201580060763.8A patent/CN107073006A/zh active Pending
- 2015-09-15 CA CA2961525A patent/CA2961525A1/en not_active Abandoned
-
2017
- 2017-03-12 IL IL251103A patent/IL251103A0/en unknown
- 2017-03-16 CL CL2017000643A patent/CL2017000643A1/es unknown
- 2017-03-23 CO CONC2017/0002772A patent/CO2017002772A2/es unknown
- 2017-03-31 EC ECIEPI201720172A patent/ECSP17020172A/es unknown
- 2017-05-05 US US15/588,495 patent/US10071984B2/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060074244A1 (en) * | 2002-07-31 | 2006-04-06 | Gellibert Francoise J | Pyridinyl substituted (1,2,3,)triazoles as inhibitors of the tgf-beta signalling pathway |
| US20140194469A1 (en) * | 2012-12-06 | 2014-07-10 | Quanticel Pharmaceuticals, Inc. | Histone demethylase inhibitors |
Non-Patent Citations (1)
| Title |
|---|
| KATHERINE S. ENGLAND ET AL.: "Optimisation of a triazolopyridine based histone demethylase inhibitor yields a potent and selective KDM2A (FBXL11) inhibitor", 《MED. CHEM. COMMUN.》 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111116571A (zh) * | 2019-12-27 | 2020-05-08 | 吉首大学 | 含恶唑及三唑双杂环的化合物及其制备与应用方法 |
| CN111116571B (zh) * | 2019-12-27 | 2022-07-12 | 吉首大学 | 含恶唑及三唑双杂环的化合物及其制备与应用方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| MX2017003464A (es) | 2017-07-13 |
| US20160108033A1 (en) | 2016-04-21 |
| CL2017000643A1 (es) | 2017-12-01 |
| JP2017527590A (ja) | 2017-09-21 |
| US20170240529A1 (en) | 2017-08-24 |
| BR112017005128A2 (pt) | 2018-07-31 |
| WO2016044342A1 (en) | 2016-03-24 |
| IL251103A0 (en) | 2017-04-30 |
| US10071984B2 (en) | 2018-09-11 |
| CO2017002772A2 (es) | 2017-06-09 |
| ES2911292T3 (es) | 2022-05-18 |
| CA2961525A1 (en) | 2016-03-24 |
| KR20170048590A (ko) | 2017-05-08 |
| SG11201702108PA (en) | 2017-04-27 |
| EP3193881A1 (en) | 2017-07-26 |
| EP3193881A4 (en) | 2018-02-21 |
| EA201790502A1 (ru) | 2017-10-31 |
| EP3193881B1 (en) | 2022-02-09 |
| JP6660060B2 (ja) | 2020-03-04 |
| US9676770B2 (en) | 2017-06-13 |
| AU2015317904A1 (en) | 2017-04-06 |
| ECSP17020172A (es) | 2017-05-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6660060B2 (ja) | ヒストンデメチラーゼ阻害剤 | |
| JP6276378B2 (ja) | ヒストンデメチラーゼ阻害剤 | |
| CN106659914B (zh) | 赖氨酸特异性脱甲基酶-1的抑制剂 | |
| JP6663866B2 (ja) | リジン特異的なデメチラーゼ−１の阻害剤 | |
| ES2834959T3 (es) | Inhibidores de histona desmetilasa | |
| CN105026372B (zh) | 组蛋白脱甲基酶抑制剂 | |
| JP6967632B2 (ja) | ヒストンデメチラーゼ阻害剤 | |
| JP6970680B2 (ja) | ヒストンデメチラーゼ阻害剤 | |
| US10174003B2 (en) | Histone demethylase inhibitors | |
| TW202304884A (zh) | 經取代之吡咯甲醯胺、其製備方法及其作為激酶抑制劑之用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20170818 |
|
| WD01 | Invention patent application deemed withdrawn after publication |